



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Dated: 16th February, 2017

To,
Mr. Kautak Upadhyay,
Manager,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No.C-1, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

Sub: Non-Compliance as per Regulation 33 of the SEBI (Listing Obligations and
Disclosure Requirements), Regulations, 2015

Ref: NSE/LIST/104007 dated 14.02.2017


Dear Sir,

With reference to the captioned subject, please find enclosed herewith consolidated Limited Review Report of the Company for the quarter ended 31st December, 2016.

Hope you find the same in order.

Thanking You

Yours Sincerely
For Parenteral Drugs (India) Limited


Aradhana Kulkarni
Company Secretary



Limited Review Report

Review Report to
**National Stock Exchange of India Limited/
Bombay Stock Exchange Limited**

We have reviewed the accompanying statement of unaudited financial results of **Parenteral Drugs (India) Limited** for the period ended **31st December, 2016** on consolidated basis. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.


A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: **INDORE**
Date: **13 FEB 2017**

For T.N. UNNI & Co.
Chartered Accountants




T.N. Unni
(Partner)
M. No. 14520
F.R.N. 004890C